

Recordati provided funding for this meeting in the form of an educational grant.
Recordati had no involvement in the organisation or content of this meeting.

Expert Debate: Combination Versus Monotherapy Strategies in Favourable Risk mRCC

Friday 5th September 2025 10.30-10.50 BST | Auditorium



Laurence Albiges

Head of Department of
Oncology, Institut Gustave
Roussy, Villejuif, France
(Chair)



Ricky Frazer

Consultant Clinical
Oncologist, Velindre
Cancer Centre,
Cardiff, UK



Will Ince

Affiliated Assistant Professor and
Consultant Clinical Oncologist,
Cambridge University NHS
Foundation Trust,
Cambridge, UK

■ Learning Objectives

By participating in this symposium, learners will be better able to:

- Articulate the clinical evidence and guidelines for use of frontline IO-based combination therapies and single-agent TKIs in favourable risk mRCC
- Develop personalised treatment strategies for patients with favourable risk mRCC, guided by clinical characteristics and patient preferences

Duration (minutes)	Topic	Speaker(s)
10:30-10:35	Welcome and introduction	Laurence Albiges
10:35-10:40	Frontline treatment in favourable risk mRCC: the role of IO-based combination therapies	Will Ince
10:40-10:45	Frontline treatment in favourable risk mRCC: the role of single-agent TKIs	Ricky Frazer
10:45-10:50	Panel discussion and key takeaways	Laurence Albiges & Panel Discussion